Tenet Healthcare's ($THC) ACCE composite score moved from 64 to 74, a 10-point jump that pushes the stock firmly into higher-conviction territory on our model. At a current price of $163.41 and a market cap of $14.19B, the stock also sits well below the average analyst target of $243.62 — a gap worth noting.
A 10-point score move is meaningful. Our composite pulls from four subscore buckets — growth, value, quality, and momentum — and a shift this size typically reflects improvement across more than one of them, not just a single data point ticking higher.
What it means
Value looks hard to ignore. A trailing P/E of 8.6 and a forward P/E of 9.6 are low multiples for a large healthcare operator. When valuation metrics sit at those levels, the value subscore tends to carry real weight in the composite. If that subscore moved, it likely pulled the overall number up by several points on its own.
Recibe el resumen semanal de ACCE
Rentabilidad de los índices, repaso de las selecciones y los mayores cambios de puntuación, cada domingo. Sin relleno.
Earnings growth is the standout figure. Year-over-year earnings growth of 87.6% is a substantial number. That kind of acceleration in the bottom line feeds directly into both the growth and quality subscores. Growth models reward earnings expansion, and quality models reward the efficiency implied by earnings growing far faster than revenue. Revenue grew 2.8% over the same period — solid but not spectacular — which means $THC is squeezing considerably more profit out of a similar top line. That dynamic is exactly what quality-oriented scoring frameworks reward.
Momentum may have contributed too. When earnings surprise to the upside and valuation stays compressed, price momentum often follows. If the stock has seen positive price action in recent weeks, the momentum subscore would reflect that and add further lift to the composite.
What to watch. A score of 74 is a positive signal, but it is not a guarantee of continued outperformance. The gap between the current price and the analyst consensus target is wide, and wide gaps can close in either direction. The low P/E multiples suggest the market is pricing in some uncertainty around earnings sustainability — whether that 87.6% earnings growth rate holds, moderates, or reverses will matter a great deal to where the score goes from here. Revenue growth at 2.8% is modest, and any pressure on hospital volumes or reimbursement rates could weigh on future earnings.
For the current price and full scorecard breakdown, visit acceinvestments.com/stocks/THC.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
